GUARDANT HEALTH INC (GH) Fundamental Analysis & Valuation
NASDAQ:GH • US40131M1099
Current stock price
85.49 USD
+1.47 (+1.75%)
At close:
86.01 USD
+0.52 (+0.61%)
After Hours:
This GH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. GH Profitability Analysis
1.1 Basic Checks
- GH had negative earnings in the past year.
- GH had a negative operating cash flow in the past year.
- GH had negative earnings in each of the past 5 years.
- GH had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -20.67%, GH is not doing good in the industry: 81.19% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.67% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-25.63%
ROA(5y)-27.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 64.46%, GH belongs to the top of the industry, outperforming 84.16% of the companies in the same industry.
- In the last couple of years the Gross Margin of GH has remained more or less at the same level.
- GH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.47%
GM growth 5Y-0.99%
2. GH Health Analysis
2.1 Basic Checks
- GH does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for GH has been increased compared to 1 year ago.
- Compared to 5 years ago, GH has more shares outstanding
- The debt/assets ratio for GH has been reduced compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of 1.57, we must say that GH is in the distress zone and has some risk of bankruptcy.
- GH has a Altman-Z score (1.57) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.57 |
ROIC/WACCN/A
WACC8%
2.3 Liquidity
- A Current Ratio of 4.84 indicates that GH has no problem at all paying its short term obligations.
- GH has a better Current ratio (4.84) than 92.08% of its industry peers.
- A Quick Ratio of 4.56 indicates that GH has no problem at all paying its short term obligations.
- GH has a Quick ratio of 4.56. This is amongst the best in the industry. GH outperforms 92.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.84 | ||
| Quick Ratio | 4.56 |
3. GH Growth Analysis
3.1 Past
- The Earnings Per Share has been growing slightly by 5.62% over the past year.
- The Revenue has grown by 32.88% in the past year. This is a very strong growth!
- GH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.92% yearly.
EPS 1Y (TTM)5.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.11%
Revenue 1Y (TTM)32.88%
Revenue growth 3Y29.76%
Revenue growth 5Y27.92%
Sales Q2Q%39.37%
3.2 Future
- GH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.17% yearly.
- The Revenue is expected to grow by 26.92% on average over the next years. This is a very strong growth
EPS Next Y17.14%
EPS Next 2Y20.22%
EPS Next 3Y24.13%
EPS Next 5Y26.17%
Revenue Next Year31%
Revenue Next 2Y29.77%
Revenue Next 3Y28.81%
Revenue Next 5Y26.92%
3.3 Evolution
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. GH Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for GH. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GH. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as GH's earnings are expected to grow with 24.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.22%
EPS Next 3Y24.13%
5. GH Dividend Analysis
5.1 Amount
- GH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
GH Fundamentals: All Metrics, Ratios and Statistics
85.49
+1.47 (+1.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-19 2026-02-19/amc
Earnings (Next)04-28 2026-04-28/amc
Inst Owners100.86%
Inst Owner Change6.01%
Ins Owners3.99%
Ins Owner Change-0.25%
Market Cap11.21B
Revenue(TTM)982.02M
Net Income(TTM)-416.28M
Analysts85.88
Price Target131.82 (54.19%)
Short Float %8.51%
Short Ratio5.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.41%
Min EPS beat(2)-38.56%
Max EPS beat(2)-2.26%
EPS beat(4)0
Avg EPS beat(4)-10.51%
Min EPS beat(4)-38.56%
Max EPS beat(4)-0.34%
EPS beat(8)0
Avg EPS beat(8)-11.47%
EPS beat(12)4
Avg EPS beat(12)0.71%
EPS beat(16)6
Avg EPS beat(16)-0.16%
Revenue beat(2)2
Avg Revenue beat(2)5%
Min Revenue beat(2)0.76%
Max Revenue beat(2)9.24%
Revenue beat(4)4
Avg Revenue beat(4)5.15%
Min Revenue beat(4)0.76%
Max Revenue beat(4)9.24%
Revenue beat(8)8
Avg Revenue beat(8)5.73%
Revenue beat(12)12
Avg Revenue beat(12)4.71%
Revenue beat(16)13
Avg Revenue beat(16)3.19%
PT rev (1m)6.95%
PT rev (3m)30.87%
EPS NQ rev (1m)-13.45%
EPS NQ rev (3m)-22.41%
EPS NY rev (1m)-11.03%
EPS NY rev (3m)-26.17%
Revenue NQ rev (1m)2.85%
Revenue NQ rev (3m)3.25%
Revenue NY rev (1m)2.91%
Revenue NY rev (3m)4.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 11.42 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.36
EYN/A
EPS(NY)-2.78
Fwd EYN/A
FCF(TTM)-1.78
FCFYN/A
OCF(TTM)-1.41
OCFYN/A
SpS7.49
BVpS-0.76
TBVpS-1.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.67% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.46% | ||
| FCFM | N/A |
ROA(3y)-25.63%
ROA(5y)-27.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.47%
GM growth 5Y-0.99%
F-Score5
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 121.57% | ||
| Cap/Sales | 4.92% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.84 | ||
| Quick Ratio | 4.56 | ||
| Altman-Z | 1.57 |
F-Score5
WACC8%
ROIC/WACCN/A
Cap/Depr(3y)84.04%
Cap/Depr(5y)160.9%
Cap/Sales(3y)4.43%
Cap/Sales(5y)10.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.11%
EPS Next Y17.14%
EPS Next 2Y20.22%
EPS Next 3Y24.13%
EPS Next 5Y26.17%
Revenue 1Y (TTM)32.88%
Revenue growth 3Y29.76%
Revenue growth 5Y27.92%
Sales Q2Q%39.37%
Revenue Next Year31%
Revenue Next 2Y29.77%
Revenue Next 3Y28.81%
Revenue Next 5Y26.92%
EBIT growth 1Y1.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year52.61%
EBIT Next 3Y33.25%
EBIT Next 5Y29.86%
FCF growth 1Y15.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.97%
OCF growth 3YN/A
OCF growth 5YN/A
GUARDANT HEALTH INC / GH Fundamental Analysis FAQ
What is the ChartMill fundamental rating of GUARDANT HEALTH INC (GH) stock?
ChartMill assigns a fundamental rating of 3 / 10 to GH.
What is the valuation status for GH stock?
ChartMill assigns a valuation rating of 1 / 10 to GUARDANT HEALTH INC (GH). This can be considered as Overvalued.
What is the profitability of GH stock?
GUARDANT HEALTH INC (GH) has a profitability rating of 1 / 10.
Can you provide the financial health for GH stock?
The financial health rating of GUARDANT HEALTH INC (GH) is 4 / 10.